Cargando…

Zhuyu Pill Alleviates Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism through the Gut–Liver Axis

Aim. The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide, but there are currently limited treatment options available. Therefore, it is necessary to research new treatment strategies. Zhuyu Pill (ZYP) is a well-known herbal recipe consisting of Huanglian (Coptidis rhiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Lu, Xu, Kunhe, Xiong, Peiyu, Zhong, Chun, Zhang, Xiaobo, Gao, Rui, Zhou, Xin, Shen, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433349/ https://www.ncbi.nlm.nih.gov/pubmed/37599938 http://dx.doi.org/10.1021/acsomega.3c01955

Ejemplares similares

Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
por: Xue, Rui, et al.
Publicado: (2021)

Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis
por: Liu, Jiaxin, et al.
Publicado: (2021)

Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease
por: Xu, Yu, et al.
Publicado: (2021)

Vitamin C and vitamin D(3) alleviate metabolic-associated fatty liver disease by regulating the gut microbiota and bile acid metabolism via the gut-liver axis
por: Chen, Qingling, et al.
Publicado: (2023)

Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis
por: Yang, Huili, et al.
Publicado: (2022)

The zhuyu pill relieves rat cholestasis by regulating the mRNA expression of lipid and bile metabolism associated genes
por: Han, Jun, et al.
Publicado: (2023)

Effects and Potential Mechanism of Zhuyu Pill Against Atherosclerosis: Network Pharmacology and Experimental Validation
por: Pan, Yingying, et al.
Publicado: (2023)

The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Association of Intestinal Permeability with Disease Severity and Treatment Outcomes
por: Zhuang, Yu-Pei, et al.
Publicado: (2022)

Volatile Oil of Amomum villosum Inhibits Nonalcoholic Fatty Liver Disease via the Gut-Liver Axis
por: Lu, Shanhong, et al.
Publicado: (2018)

The role of microbiome in the pathogenesis of oral-gut-liver axis between periodontitis and nonalcoholic fatty liver disease
por: Chen, Tsung-Po, et al.
Publicado: (2023)

The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
por: Ni, Yiming, et al.
Publicado: (2022)

Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis
por: Wang, Wei, et al.
Publicado: (2023)

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease
por: Wang, Caihua, et al.
Publicado: (2019)

Multiple Mechanisms of Shenqi Pill in Treating Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Molecular Docking
por: Tong, Xiaojuan, et al.
Publicado: (2022)

Mechanism of interventional effect and targets of Zhuyu pill in regulating and suppressing colitis and cholestasis
por: Yu, Han, et al.
Publicado: (2022)

Lycium ruthenicum Murr. alleviates nonalcoholic fatty liver in mice
por: Lu, Keke, et al.
Publicado: (2020)

Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease
por: Yu, Jiake, et al.
Publicado: (2021)

Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis
por: Yoon, Sang Jun, et al.
Publicado: (2023)

Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling
por: Ren, Zi-Lin, et al.
Publicado: (2022)

Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease
por: Boursier, Jerome, et al.
Publicado: (2015)

The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
por: Roychowdhury, Sanjoy, et al.
Publicado: (2018)

Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease
por: Sharpton, Suzanne R., et al.
Publicado: (2018)

New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease
por: Bertran, Laia, et al.
Publicado: (2022)

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
por: Arab, Juan P., et al.
Publicado: (2016)

Periodontal disease–related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral‐liver axis
por: Kuraji, Ryutaro, et al.
Publicado: (2021)

Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut–Liver Axis
por: Xu, Ye, et al.
Publicado: (2023)

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
por: Li, Hu, et al.
Publicado: (2022)

Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux
por: Liu, Cong, et al.
Publicado: (2018)

Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis
por: Endo, Hitoshi, et al.
Publicado: (2013)

Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
por: Owaki, Takashi, et al.
Publicado: (2022)

Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease
por: Jin, Li-ting, et al.
Publicado: (2023)

Retraction: Nonalcoholic fatty liver disease, diet and gut microbiota
por: Finelli, Carmine, et al.
Publicado: (2017)

Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases
por: Kim, Han-Na, et al.
Publicado: (2019)

Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease
por: Zhao, Yuzhen, et al.
Publicado: (2019)

Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis
por: Mohammadi, Zahra, et al.
Publicado: (2022)

Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease
por: Lin, Chuan-Hao, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
por: Fianchi, Francesca, et al.
Publicado: (2021)

Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
por: Han, Ting-Rui, et al.
Publicado: (2023)

Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats
por: Liu, Boyan, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_se8qd089ejhonuh1rcc3bu321c